Dr. Reddy's Laboratories Limited Upgraded to Overweight by Barclays (RDY)

Share on StockTwits

Dr. Reddy's Laboratories Limited (NYSE:RDY) was upgraded by investment analysts at Barclays to an “overweight” rating in a note issued to investors on Thursday.

Several other analysts have also recently commented on the stock. Analysts at TheStreet downgraded shares of Dr. Reddy's Laboratories Limited from a “buy” rating to a “hold” rating in a research note on Thursday, May 15th. Separately, analysts at Morgan Stanley downgraded shares of Dr. Reddy's Laboratories Limited from an “overweight” rating to an “equal weight” rating in a research note on Wednesday, May 14th. Finally, analysts at Bank of America downgraded shares of Dr. Reddy's Laboratories Limited from a “buy” rating to an “underperform” rating in a research note on Wednesday, May 14th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and two have issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average target price of $35.00.

Shares of Dr. Reddy's Laboratories Limited (NYSE:RDY) opened at 38.67 on Thursday. Dr. Reddy's Laboratories Limited has a 52 week low of $31.32 and a 52 week high of $47.93. The stock’s 50-day moving average is $43.29 and its 200-day moving average is $42.35. The company has a market cap of $6.578 billion and a price-to-earnings ratio of 18.38.

Dr. Reddy's Laboratories Limited (NYSE:RDY) last released its earnings data on Tuesday, May 13th. The company reported $0.47 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.52 by $0.05. The company had revenue of $580.00 million for the quarter, compared to the consensus estimate of $557.00 million. Analysts expect that Dr. Reddy's Laboratories Limited will post $2.21 EPS for the current fiscal year.

Dr. Reddy’s Laboratories Limited (NYSE:RDY) is an integrated global pharmaceutical company.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.

Latest News

Pokemon Rumor Helps Nintendo Rise
Pokemon Rumor Helps Nintendo Rise
Barcadi Offering Pricey New Rum Collection
Barcadi Offering Pricey New Rum Collection
Sony Announces PS4 Sales of 10 Million
Sony Announces PS4 Sales of 10 Million
Rory McIlroy is the PGA Champion
Rory McIlroy is the PGA Champion
Pfizer Sued Due to Worry Lipitor Could Cause Diabetes
Pfizer Sued Due to Worry Lipitor Could Cause Diabetes
Gannett Acquires Cars.com, Splits in Two
Gannett Acquires Cars.com, Splits in Two


Leave a Reply

 
© 2006-2014 The Legacy. Subscribe